Notice Regarding Revision of Consolidated Earnings Forecast for the Fiscal Year Ending December 2025

We hereby announce that we have revised the consolidated earnings forecast for the fiscal year ending December 2025 (January 1, 2025 - December 31, 2025), which was originally announced on

February 14, 2025, as follows.

1. Revision of Consolidated Earnings Forecast Figures for the Current Fiscal Year

   	Revenue	Operating Profit	Ordinary Profit	Net Income Attributable to Owners of the Parent	Net Income per Share
   Previous Forecast (A)	million yen	million yen	million yen	million yen	yen
   	1,350	-5,800	-5,820	-5,850	-20.43
   Revised Forecast (B)	880	-6,270	-6,290	-6,320	-17.82
   Change Amount (B−A)	-470	-470	-470	-470
   Change Rate (%)	-34.8	-8.1	-8.1	-8.0
   [For Reference] Actual Results for the Previous Fiscal Year (Fiscal Year Ended December 2024)	643	-9,109	-7,537	-28,128	-119.53

2. Reason for Revision

Sales of the progeria treatment drug Zokinvy have been trending below the initial plan. In addition, regarding the expanded newborn screening tests commissioned to AnGes Clinical Research Laboratory (ACRL), the projected number of tests for the full year is expected to decrease compared to the plan due to factors such as a revision of the timing for the installation of new equipment that was planned at the beginning of the fiscal year.

Furthermore, as announced on September 4, 2025 in the release titled "Notice of Expansion of License Agreement Scope by Our Subsidiary", our subsidiary EmendoBio Inc. entered into an agreement with Anocca AB of Sweden to expand the scope of application for the OMNI nuclease usage rights. Due to changes in Anocca AB's development schedule, the license revenue originally expected to be recorded within 2025 is now projected to be recorded in 2026.

As a result of these factors, net sales are expected to fall below the initial plan, and we have accordingly revised our full-year earnings forecast as stated above.